Can a Triple-Drug combo outsmart advanced pancreatic cancer?

NCT ID NCT07773363

Not yet recruiting Disease control Sponsor: Tang-Du Hospital Source: ClinicalTrials.gov ↗

First seen Aug 19, 2026 · Last updated Aug 20, 2026 · Updated 1 time

Summary

This phase 2 trial is testing whether combining an experimental drug called retlirafusp alfa with apatinib and chemotherapy can help people with advanced pancreatic cancer whose disease has worsened after initial treatment. The study will enroll about 37 adults with locally advanced or metastatic pancreatic cancer to see if the combination can delay cancer progression and improve survival. Researchers will also monitor safety and how well the treatment shrinks tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: retlirafusp alfa combined with apatinib and chemotherapy
What this could lead to: If successful, this combination could offer a new second-line treatment option for people with advanced pancreatic cancer, potentially extending life or slowing tumor growth.
What could go wrong: This is an early-phase, small study (37 participants) without a comparison group, so results may not be definitive. The combination may cause significant side effects and may not improve outcomes for all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

malignant pancreatic neoplasm pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PANCREATIC CANCER

More trials for these conditions

Other studies related to the condition(s) this trial covers.